111051-31-1

Basic information

• Product Name: (+)-Bamethan
• Synonyms: (+)-Bamethan
• CAS NO: 111051-31-1
• Molecular Formula: C₁₂H₁₉NO₂
• Molecular Weight: 209.28
• Mol File: 111051-31-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (+)-Bamethan(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-Bamethan(111051-31-1)
• EPA Substance Registry System: (+)-Bamethan(111051-31-1)

Safety Data

• Hazardous Substances Data: 111051-31-1(Hazardous Substances Data)

Usage

General Description

(+)-Bamethan is a chemical compound that belongs to the class of beta-adrenergic agonists. It is primarily used as a bronchodilator in the treatment of breathing-related issues such as asthma and chronic obstructive pulmonary disease (COPD). As a beta-adrenergic agonist, (+)-Bamethan works by stimulating the beta-2 adrenergic receptors in the smooth muscles of the airways, leading to relaxation and dilation of the air passages. This results in improved airflow to the lungs, making it easier for the individual to breathe. Additionally, (+)-Bamethan may also have some mild vasoconstrictive properties, which can help reduce inflammation and swelling in the airways. Although it is effective in treating respiratory conditions, it may also have potential side effects such as tremors, palpitations, and increased heart rate. Therefore, it is important to use (+)-Bamethan under the supervision of a healthcare professional.

Upstream product

• 123-11-5 4-methoxy-benzaldehyde 
• 6388-72-3 2-(4-methoxyphenyl)oxirane 
• 5324-15-2 4'-benzoyloxy-2-bromoacetophenone 
• 18986-11-3 2-butylamino-1-(4-hydroxy-phenyl)-ethanone 

Downstream Products

• 7339-87-9 4-hydroxyphenylacetaldehyde 
• 132034-25-4 N-Butyl-C-((S)-7,7-dimethyl-2-oxo-bicyclo[2.2.1]hept-1-yl)-N-[2-hydroxy-2-(4-hydroxy-phenyl)-ethyl]-methanesulfonamide 

Relevant articles and documents

BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASES

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a non-alcoholic fatty liver disease (NAFLD), such as non-alcoholic steatohepatitis (NASH), wherein X, R1, R2, R3 and n have meanings as provided in the description.

Pharmaceutical formula

The present invention concerns a pharmacological vehicle or carrier system, which makes possible administration of the active ingredient with a high absorption thereof in the blood circulation of the patient treated therewith, in particular also in the case of oral administration. The pharmacological vehicle system according to the invention comprises ultrafine particles of a reaction product of a reactive derivative of an at least dibasic inorganic acid or an alkane-carboxylic acid having 2 or 3 carboxyl groups and optionally one or two hydroxy groups, wherein one bond of the dibasic inorganic acid or one carboxy group of the alkane-carboxylic acid is bonded to a pharmacological active ingredient containing a hydroxy group, SH group and/or a primary or secondary amino group having a ractive hydrogen atom on this group, and the other bond is bonded to the free hydroxy group of a glycerolipid having at least one free hydroxy group on the glycerol. The invention further concerns these reaction products and a process for the preparation of ultrafine particles of these reaction products.